Department of Ophthalmology, Gunma University Graduate School of Medicine, Maebashi, Japan
Search for other papers by Kazuma Saito in
Google Scholar
PubMed
Search for other papers by Kazuhiko Horiguchi in
Google Scholar
PubMed
Search for other papers by Sayaka Yamada in
Google Scholar
PubMed
Search for other papers by Battsetseg Buyandalai in
Google Scholar
PubMed
Search for other papers by Emi Ishida in
Google Scholar
PubMed
Search for other papers by Shunichi Matsumoto in
Google Scholar
PubMed
Search for other papers by Satoshi Yoshino in
Google Scholar
PubMed
Search for other papers by Yasuyo Nakajima in
Google Scholar
PubMed
Search for other papers by Eijiro Yamada in
Google Scholar
PubMed
Search for other papers by Tsugumichi Saito in
Google Scholar
PubMed
Search for other papers by Atsushi Ozawa in
Google Scholar
PubMed
Search for other papers by Yuki Tajika in
Google Scholar
PubMed
Search for other papers by Hideo Akiyama in
Google Scholar
PubMed
Search for other papers by Masanobu Yamada in
Google Scholar
PubMed
Thyroid hormones are critical for the development of opsins involved in color vision. Hypothyroid mice show delayed M-opsin development and expanded distribution of S-opsin on the retina. However, the effects of maternal hypothyroidism on opsin development remain unknown. This study investigates the effects of congenital central hypothyroidism and maternal hypothyroidism on opsin development in thyrotropin-releasing hormone knockout (TRH−/−) mice. We examined the mRNA expression and protein distribution of S/M-opsin on postnatal days (P)12 and 17, as well as mRNA expression of type 2 and 3 iodothyronine deiodinase (DIO2 and DIO3, respectively) in the retina and type 1 iodothyronine deiodinase (DIO1) in the liver at P12 in TRH+/− mice born to TRH+/− or TRH−/− dams, and conducted S/M-opsin analysis in TRH+/+ or TRH−/− mice born to TRH+/− dams at P12, P17, and P30. M-opsin expression was lower in TRH+/− mice born to TRH−/− dams than in those born to TRH+/− dams, whereas S-opsin expression did not significantly differ between them. DIO1, DIO2, and DIO3 mRNA expression levels were not significantly different between the two groups; therefore, thyroid function in peripheral tissues in the pups was similar. S/M-opsin expression did not significantly differ between the TRH+/+ and TRH−/− mice born to TRH+/− dams on any postnatal day. These results demonstrate that maternal hypothyroidism causes M-opsin developmental delay during the early developmental stages of neonatal mice, and TRH−/− mice, a model of congenital central hypothyroidism, born to a euthyroid dam do not have delayed opsin development.
Search for other papers by Yi Wang in
Google Scholar
PubMed
NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China
Search for other papers by Qi-Ling Shen in
Google Scholar
PubMed
Search for other papers by Qi Xin in
Google Scholar
PubMed
Search for other papers by Bei Sun in
Google Scholar
PubMed
Search for other papers by Shi Zhang in
Google Scholar
PubMed
Search for other papers by Qian-Hua Fang in
Google Scholar
PubMed
Search for other papers by Ying-Xin Shi in
Google Scholar
PubMed
Search for other papers by Wen-Yan Niu in
Google Scholar
PubMed
Search for other papers by Jing-Na Lin in
Google Scholar
PubMed
Search for other papers by Chun-Jun Li in
Google Scholar
PubMed
Medium-chain acyl-CoA dehydrogenase (MCAD) is one of the significant enzymes involved in the β-oxidation of mitochondrial fatty acids. MCAD deficiency affects the β-oxidation of fatty acid and leads to lipid deposition in multiple organs, but little is known about its importance in nonalcoholic steatohepatitis (NASH). Empagliflozin is revealed to effectively improve NASH by increasing research, whereas the specific mechanism still has to be explored. Human liver tissues of patients with or without NASH were obtained for proteomic analysis to screen proteins of interest. db/db mice were given empagliflozin by gavage for 8 weeks. The expression of MCAD and signaling molecules involved in hepatic lipid metabolism was evaluated in human liver, mice and HL7702 cells. We found that the MCAD levels in the liver were significantly reduced in NASH patients compared to patients without NASH. Protein–protein interaction network analysis showed that MCAD was highly correlated with forkhead box A2 (FOXA2) and protein kinase AMP-activated catalytic subunit alpha (PRKAA). AMPK/FOXA2/MCAD signaling pathway was detected to be inhibited in the liver of NASH patients. Decreased expression of MCAD was also observed in the livers of db/db mice and hepatocyte treated with palmitic acid and glucose. Of note, empagliflozin could upregulate MCAD expression by activating AMPK/FOXA2 signaling pathway, reduce lipid deposition and improve NASH in vivo and in vitro. This research demonstrated that MCAD is a key player of hepatic lipid deposition and its targeting partially corrects NASH. MCAD thus may be a potential therapeutic target for the treatment of NASH.
Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Shanghai, China
Medical College, Anhui University of Science and Technology, Huainan, China
Search for other papers by Dongmei Lan in
Google Scholar
PubMed
Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Shanghai, China
Medical College, Anhui University of Science and Technology, Huainan, China
Search for other papers by Shengcai Qi in
Google Scholar
PubMed
Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Shanghai, China
Medical College, Anhui University of Science and Technology, Huainan, China
Search for other papers by Chao Yao in
Google Scholar
PubMed
Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Shanghai, China
Medical College, Anhui University of Science and Technology, Huainan, China
Search for other papers by Xue Li in
Google Scholar
PubMed
Department of Endodontics, Shanghai Stomatological Hospital, Fudan University, Shanghai, China
Search for other papers by Haijiang Liu in
Google Scholar
PubMed
School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong SAR, China
Center for Neuromusculoskeletal Restorative Medicine, Hong Kong Science Park, Hong Kong SAR, China
Search for other papers by Dan Wang in
Google Scholar
PubMed
Department of Preventive Dentistry, Shanghai Stomatological Hospital, Fudan University, Shanghai, China
Search for other papers by Yan Wang in
Google Scholar
PubMed
Quercetin has been shown to have a wide range of beneficial effects, such as anti-inflammation, anti-oxidation and immunomodulation. The study was designed to explore the role and molecular mechanisms of quercetin on the protective effect of bone marrow-derived mesenchymal stem cells (BMSCs) under oxidative stress in vitro. BMSCs were isolated from 4-week-old male Sprague–Dawley rats. Upon H2O2 stimulation in vitro, the effects of quercetin on the proliferation, anti-oxidation and osteogenic differentiation of BMSCs were evaluated by Cell Counting Kit-8, reactive oxygen species analysis, Western blot (WB), real-time PCR (RT-PCR), alkaline phosphatase staining and alizarin red staining. Additionally, ferroptosis-related markers were examined by WB, RT-PCR and Mito-FerroGreen. Finally, PI3K/AKT/mTOR signaling pathway was explored in these processes. We found that quercetin significantly maintained BMSCs viability upon H2O2 stimulation. Quercetin upregulated protein (ALP, OPN and RUNX2) and mRNA (Alp, Opn, Ocn and Runx2) levels of osteogenic markers, downregulated ROS levels and upregulated antioxidative gene expressions (Nrf2, Cat, Sod-1 and Sod-2) compared with the H2O2 group. The ferroptosis in BMSCs was activated after H2O2 stimulation, and the phosphorylation level of PI3K, AKT and mTOR was upregulated in H2O2-stimulated BMSCs. More importantly, quercetin inhibited ferroptosis and the phosphorylation level of PI3K, AKT and mTOR were downregulated after quercetin treatment. We conclude that quercetin maintained the viability and the osteoblastic differentiation of BMSCs upon H2O2 stimulation, potentially via ferroptosis inhibition by PI3K/AKT/mTOR pathway.
Search for other papers by Aprajita S Yadav in
Google Scholar
PubMed
Search for other papers by Nina Isoherranen in
Google Scholar
PubMed
Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, Washington, USA
Search for other papers by Katya B Rubinow in
Google Scholar
PubMed
Vitamin A (retinol) is an essential, fat-soluble vitamin that plays critical roles in embryonic development, vision, immunity, and reproduction. Severe vitamin A deficiency results in profound embryonic dysgenesis, blindness, and infertility. The roles of bioactive vitamin A metabolites in regulating cell proliferation, cellular differentiation, and immune cell function form the basis of their clinical use in the treatment of dermatologic conditions and hematologic malignancies. Increasingly, vitamin A also has been recognized to play important roles in cardiometabolic health, including the regulation of adipogenesis, energy partitioning, and lipoprotein metabolism. While these roles are strongly supported by animal and in vitro studies, they remain poorly understood in human physiology and disease. This review briefly introduces vitamin A biology and presents the key preclinical data that have generated interest in vitamin A as a mediator of cardiometabolic health. The review also summarizes clinical studies performed to date, highlighting the limitations of many of these studies and the ongoing controversies in the field. Finally, additional perspectives are suggested that may help position vitamin A metabolism within a broader biological context and thereby contribute to enhanced understanding of vitamin A’s complex roles in clinical cardiometabolic disease.
Center for Diabetes & Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA
Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA
Search for other papers by Rebecca K Davidson in
Google Scholar
PubMed
Center for Diabetes & Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA
Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA
Search for other papers by Staci A Weaver in
Google Scholar
PubMed
Center for Diabetes & Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA
Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA
Search for other papers by Nolan Casey in
Google Scholar
PubMed
Center for Diabetes & Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA
Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA
Search for other papers by Sukrati Kanojia in
Google Scholar
PubMed
Search for other papers by Elise Hogarth in
Google Scholar
PubMed
Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA
Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
Search for other papers by Rebecca Schneider Aguirre in
Google Scholar
PubMed
Center for Diabetes & Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA
Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Search for other papers by Emily K Sims in
Google Scholar
PubMed
Center for Diabetes & Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA
Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Richard L. Roudebush VA Medical Center, Indianapolis, Indiana, USA
Search for other papers by Carmella Evans-Molina in
Google Scholar
PubMed
Center for Diabetes & Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA
Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Search for other papers by Jason M Spaeth in
Google Scholar
PubMed
Type 2 diabetes (T2D) is associated with loss of transcription factors (TFs) from a subset of failing β-cells. Among these TFs is Pdx1, which controls the expression of numerous genes involved in maintaining β-cell function and identity. Pdx1 activity is modulated by transcriptional coregulators and has recently been shown, through an unbiased screen, to interact with the Chd4 ATPase subunit of the nucleosome remodeling and deacetylase complex. Chd4 contributes to the maintenance of cellular identity and functional status of numerous different cell types. Here, we demonstrated that Pdx1 dynamically interacts with Chd4 under physiological and stimulatory conditions within islet β-cells and established a fundamental role for Chd4 in regulating insulin secretion and modulating numerous Pdx1-bound genes in vitro, including the MafA TF, where we discovered Chd4 is bound to the MafA region 3 enhancer. Furthermore, we found that Pdx1:Chd4 interactions are significantly compromised in islet β-cells under metabolically induced stress in vivo and in human donor tissues with T2D. Our findings establish a fundamental role for Chd4 in regulating insulin secretion and modulating Pdx1-bound genes in vitro, and disruption of Pdx1:Chd4 interactions coincides with β-cell dysfunction associated with T2D.
Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, Washington, USA
Search for other papers by Rohita Rangu in
Google Scholar
PubMed
Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA
Search for other papers by Pandora L Wander in
Google Scholar
PubMed
Search for other papers by Breanne M Barrow in
Google Scholar
PubMed
Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, Washington, USA
Search for other papers by Sakeneh Zraika in
Google Scholar
PubMed
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Following initial infection of airway epithelia, SARS-CoV-2 invades a wide range of cells in multiple organs, including pancreatic islet cells. Diabetes is now recognised as a risk factor for severe COVID-19 outcomes, including hospitalisation and death. Additionally, COVID-19 is associated with a higher risk of new-onset diabetes and metabolic complications of diabetes. One mechanism by which these deleterious outcomes may occur is via the destruction of insulin-producing islet β cells, either directly by SARS-CoV-2 entry into β cells or indirectly due to inflammation and fibrosis in the surrounding microenvironment. While the canonical pathway of viral entry via angiotensin-converting enzyme 2 (ACE2) has been established as a major route of SARS-CoV-2 infection in the lung, it may not be solely responsible for viral entry into the endocrine pancreas. This is likely due to the divergent expression of viral entry factors among different tissues. For example, expression of ACE2 has not been unequivocally demonstrated in β cells. Thus, it is important to understand how other proteins known to be highly expressed in pancreatic endocrine cells may be involved in SARS-CoV-2 entry, with the view that these could be targeted to prevent the demise of the β cell in COVID-19. To that end, this review discusses alternate receptors of SARS-CoV-2 (CD147 and GRP78), as well as mediators (furin, TMPRSS2, cathepsin L, ADAM17, neuropilin-1, and heparan sulphate) that may facilitate SARS-CoV-2 entry into pancreatic islets independent of or in conjunction with ACE2.
Search for other papers by Marina C Muñoz in
Google Scholar
PubMed
Search for other papers by Verónica G Piazza in
Google Scholar
PubMed
Search for other papers by Valeria Burghi in
Google Scholar
PubMed
Search for other papers by Jorge F Giani in
Google Scholar
PubMed
Search for other papers by Carolina S Martinez in
Google Scholar
PubMed
Search for other papers by Nadia S Cicconi in
Google Scholar
PubMed
Search for other papers by Nadia V Muia in
Google Scholar
PubMed
Search for other papers by Yimin Fang in
Google Scholar
PubMed
Cardiology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Search for other papers by Sergio Lavandero in
Google Scholar
PubMed
Search for other papers by Ana I Sotelo in
Google Scholar
PubMed
Search for other papers by Andrzej Bartke in
Google Scholar
PubMed
Search for other papers by Patricia A Pennisi in
Google Scholar
PubMed
Search for other papers by Fernando P Dominici in
Google Scholar
PubMed
Search for other papers by Johanna G Miquet in
Google Scholar
PubMed
Growth hormone (GH) exerts major actions in cardiac growth and metabolism. Considering the important role of insulin in the heart and the well-established anti-insulin effects of GH, cardiac insulin resistance may play a role in the cardiopathology observed in acromegalic patients. As conditions of prolonged exposure to GH are associated with a concomitant increase of circulating GH, IGF1 and insulin levels, to dissect the direct effects of GH, in this study, we evaluated the activation of insulin signaling in the heart using four different models: (i) transgenic mice overexpressing GH, with chronically elevated GH, IGF1 and insulin circulating levels; (ii) liver IGF1-deficient mice, with chronically elevated GH and insulin but decreased IGF1 circulating levels; (iii) mice treated with GH for a short period of time; (iv) primary culture of rat cardiomyocytes incubated with GH. Despite the differences in the development of cardiomegaly and in the metabolic alterations among the three experimental mouse models analyzed, exposure to GH was consistently associated with a decreased response to acute insulin stimulation in the heart at the receptor level and through the PI3K/AKT pathway. Moreover, a blunted response to insulin stimulation of this signaling pathway was also observed in cultured cardiomyocytes of neonatal rats incubated with GH. Therefore, the key novel finding of this work is that impairment of insulin signaling in the heart is a direct and early event observed as a consequence of exposure to GH, which may play a major role in the development of cardiac pathology.
Division of Advanced Diagnostics, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
Search for other papers by Jianqiu Gu in
Google Scholar
PubMed
Search for other papers by Weijuan Shao in
Google Scholar
PubMed
Department of Cardiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People’s Republic of China
Search for other papers by Dinghui Liu in
Google Scholar
PubMed
Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
Search for other papers by Jia Nuo Feng in
Google Scholar
PubMed
Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, People’s Republic of China
Search for other papers by Juan Pang in
Google Scholar
PubMed
Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
Banting and Best Diabetes Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
Search for other papers by Tianru Jin in
Google Scholar
PubMed
Although canonical Wnt signaling pathway activation was shown to negatively regulate adipogenesis, recent investigations suggest that Wnt pathway effectors TCF7L2 and β-catenin (β-cat) in adipose tissues are also involved in energy homeostasis during adulthood. In assessing the metabolic beneficial effect of GLP-1-based diabetes drugs in high-fat diet (HFD)-challenged mice, we observed that liraglutide treatment affected the expression of a battery of adipose tissue-specific genes, including those that encode adiponectin and leptin, mainly in epididymal white adipose tissue (eWAT). Fourteen-week HFD challenge repressed TCF7L2 and β-cat S675 phosphorylation in eWAT, while such repression was reversed by liraglutide treatment (150 µg/kg body weight daily) during weeks 10–14. In Glp1r−/− mice, liraglutide failed in stimulating TCF7L2 or β-cat in eWAT. We detected Glp1r expression in mouse eWAT and its level is enriched in its stromal vascular fraction (SVF). Mouse eWAT-SVF showed reduced expression of Tcf7l2 and its Tcf7l2 level could not be stimulated by liraglutide treatment; while following adipogenic differentiation, rat eWAT-SVF showed elevated Tcf7l2 expression. Direct in vitro liraglutide treatment in eWAT-SVF stimulated CREB S133, β-cat S675 phosphorylation, and cellular cAMP level. Thus, cAMP/β-cat signaling cascade can be stimulated by liraglutide in eWAT via GLP-1R expressed in eWAT-SVF.
Search for other papers by Xuefeng Peng in
Google Scholar
PubMed
Search for other papers by Fang He in
Google Scholar
PubMed
Search for other papers by Yanling Mao in
Google Scholar
PubMed
Search for other papers by Yihui Lin in
Google Scholar
PubMed
Search for other papers by Jingwen Fang in
Google Scholar
PubMed
Search for other papers by Yangchun Chen in
Google Scholar
PubMed
Search for other papers by Zhichun Sun in
Google Scholar
PubMed
Search for other papers by Yafen Zhuo in
Google Scholar
PubMed
Search for other papers by Jianjia Jiang in
Google Scholar
PubMed
We tried to unveil the clinical significance of miR-146a as a biomarker in M2 macrophage polarization in diabetic wound healing. Initially, we found reduced miR-146a in macrophages of diabetic patients. Next, dual-luciferase assay verified that toll-like receptor 4 (TLR4) was a target gene of miR-146 and was negatively regulated by miR-146. Moreover, after ectopic expression and depletion experiments of miR-146 and/or TLR4, lipopolysaccharide-induced inflammatory response of macrophages was detected. The results revealed that overexpression of miR-146a promoted the M2 macrophage polarization by suppressing the TLR4/nuclear factor-kappaB (NF-κB) axis, so as to enhance wound healing in diabetic ulcers. Further, mouse models with diabetic ulcers were established to investigate the effects of miR-146a on diabetic wound healing in vivo, which revealed that miR-146a promoted wound healing in diabetic ulcers by inhibiting the TLR4/NF-κB axis. In conclusion, we demonstrate that miR-146a can induce M2 macrophage polarization to enhance wound healing in diabetic ulcers by inhibiting the TLR4/NF-κB axis.
Search for other papers by Shalinee Dhayal in
Google Scholar
PubMed
Search for other papers by Kaiyven Afi Leslie in
Google Scholar
PubMed
Search for other papers by Mohammad Baity in
Google Scholar
PubMed
Search for other papers by Pouria Akhbari in
Google Scholar
PubMed
Search for other papers by Sarah J Richardson in
Google Scholar
PubMed
Search for other papers by Mark A Russell in
Google Scholar
PubMed
Search for other papers by Noel G Morgan in
Google Scholar
PubMed
During the development of type 1 diabetes, interferons (IFN) are elaborated from islet-infiltrating immune cells and/or from virally infected β-cells. They act via specific receptors to increase, acutely, the phosphorylation of the transcription factors STAT1 and 2. However, the longer-term impacts of chronic IFN stimulation are poorly understood and were investigated in the current study. Human EndoC-βH1 cells were treated with IFNα, IFNγ or IFNλ either acutely (<2 h) or chronically (≥24 h) and STAT phosphorylation, expression and activity were assessed by Western blotting and transcriptional reporter assays. Exposure of β-cells to IFNα or IFNλ induced a swift increase in the phosphorylation of both STAT1 and STAT2, whereas IFNγ increased only pSTAT1. Over more extended periods (≥24 h), STAT phosphorylation declined but STAT1 and STAT2 expression were enhanced in a sustained manner. All IFNs stimulated ISRE transcriptional activity (but with different time courses), whereas GAS activity was responsive only to IFNγ. The re-addition of a second bolus of IFNα, 24 h after an initial dose, failed to cause renewed STAT1/2 phosphorylation. By contrast, when IFNγ was added 24 h after exposure to IFNα, rapid STAT1 phosphorylation was re-initiated. Exposure of β-cells to IFNs leads to rapid, transient, STAT phosphorylation and to slower and more sustained increases in total STAT1/2 levels. The initial phosphorylation response is accompanied by marked desensitisation to the cognate agonist. Together, the results reveal that the response of β-cells to IFNs is regulated both temporally and quantitatively to achieve effective signal integration.
